Search

Displaying results 4681 - 4690 of 7063 in total
  1. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000] … Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).

  2. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … [L41635] This drug was approved by the FDA on April 26, 2022.[L41645]

  3. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma

  4. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.

  5. Drug

    Toll-like receptor 9

    go.drugbank.com/drugs/DB15320
    Investigational

    Toll-like receptor 9 is under investigation in clinical trial NCT03007732 (Pembrolizumab in Combination With Intratumoral SD-101 Therapy).

    Categories: DNA-Binding Proteins
  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Factor Xa Inhibitors
  7. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.

  8. Drug

    Letaxaban

    go.drugbank.com/drugs/DB11984
    Investigational

    Letaxaban has been used in trials studying the treatment and prevention of Venous Thromboembolism and Acute Coronary Syndrome.

    Categories: Factor Xa Inhibitors
  9. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548]. … The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  10. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.